FDA authorizes Pfizer-BioNTech COVID-19 vaccine for adolescents
The U.S. Food and Drug Administration (FDA) expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine to include adolescents ages 12 to 15 years. Read More
Leveraging optofluidics to make therapeutic antibody discovery easier
The need for speed and accuracy in the development of therapeutic antibodies has prompted Berkeley Lights to upgrade its optofluidic tools to help customers improve the quality of their therapeutic antibody products. John Proctor, PhD, senior vice president of antibody therapeutics at Berkeley Lights, spoke with ScienceBoard.net about some technological advancements the company has recently launched. Read More
Novavax posts positive preclinical results for flu/COVID-19 vaccine
Novavax is highlighting positive preclinical results for a combination influenza/COVID-19 vaccine. Read More
Inovio touts COVID-19 phase II vaccine results
Inovio is highlighting results from its phase II clinical trial evaluating its COVID-19 DNA vaccine. Read More
Altimmune's intranasal COVID-19 vaccine shows sterilizing potential
Preclinical data for Altimmune's intranasal AdCOVID vaccine candidate show the drug has sterilizing immunity potential after a single dose. Read More
SARS-CoV-2 vaccine candidate shows promise against variants
A pancoronavirus vaccine candidate created by the Infectious Disease Research Institute, the Duke Human Vaccine Institute, and 3M shows potential to protect against variants of SARS-CoV-2, according to a study published May 10 in Nature. Read More
Pfizer, BioNTech initiate rolling submission of BLA for COVID-19 vaccine
Pfizer and BioNTech announced on Friday that they have started a biologics license application (BLA) with the U.S. Food and Drug Administration for approval of their messenger RNA vaccine to prevent COVID-19 in individuals ages 16 years and older. Read More
GSK, Vir start EMA rolling review for anti-SARS-CoV-2 antibody
GlaxoSmithKline (GSK) and Vir Biotechnology have announced that the European Medicines Agency (EMA) has started a rolling review of data on sotrovimab, an investigational dual-action SARS-CoV-2 monoclonal antibody. Read More
Moderna booster produces antibodies against SARS-CoV-2 variants
Moderna announced that initial results from a phase II study suggest a single booster dose of its messenger RNA (mRNA) vaccine candidates mRNA-1273 or mRNA-1273.351 given to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants. Read More
Novavax COVID vaccine effective vs. B.1.351 variant, inks deal with Gavi
Novavax announced results of a phase IIB trial of its COVID-19 candidate vaccine (NVX-CoV2373) published May 5 in the New England Journal of Medicine that suggest the vaccine is effective against the B.1.351 variant prevalent in South Africa. Read More
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter